Non-small cell carcinoma of the lung. Credit: Ed Uthman/Flickr.

Incyte has partnered with AstraZeneca’s biologics research and development division MedImmune to evaluate the combination of epacadostat and Imfinzi (durvalumab) in a Phase III clinical trial to treat non-small cell lung cancer (NSCLC).

Incyte’s epacadostat is an investigational and selective inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) enzyme, while Imfinzi is a human monoclonal antibody developed to target PD-L1.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase III trial will compare the safety and efficacy of the combination with Imfinzi alone in locally advanced (Stage III) unresectable NSCLC patients who have not progressed after platinum-based chemotherapy given in conjunction with radiation therapy (CRT).

Incyte chief medical officer Steven Stein said: “We are pleased to expand our ongoing clinical collaboration with AstraZeneca and to further explore the potential of epacadostat in patients with locally-advanced unresectable lung cancer.

“We look forward to beginning this additional pivotal trial for epacadostat, as we seek to position IDO1 enzyme inhibition as a key component of combination immunotherapy.”

“Imfinzi has shown exciting clinical potential in treating patients with locally advanced lung cancer.”

While the trial will be co-funded by both firms, it will be conducted by AstraZeneca and is scheduled to commence patient enrolment in the first half of next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AstraZeneca chief medical officer and Global Medicines Development executive vice-president Sean Bohen said: “Imfinzi has shown exciting clinical potential in treating patients with locally advanced lung cancer.

“We are pleased to build on recent data from the PACIFIC trial to further explore how Imfinzi, in combination with an IDO1 enzyme inhibitor, could provide additional benefit to patients with locally advanced lung cancer.”

Upon evaluation in single-arm studies, epacadostat is reported to have demonstrated results when combined with immune checkpoint inhibitors in patients suffering from NSCLC, melanoma, renal cell carcinoma, bladder cancer and squamous cell carcinoma of the head and neck.